Compare CHE & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHE | IRTC |
|---|---|---|
| Founded | 1970 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 4.8B |
| IPO Year | 1994 | 2016 |
| Metric | CHE | IRTC |
|---|---|---|
| Price | $399.18 | $117.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | ★ $498.00 | $207.54 |
| AVG Volume (30 Days) | 229.2K | ★ 625.6K |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 0.60% | N/A |
| EPS Growth | N/A | ★ 61.71 |
| EPS | ★ 18.34 | N/A |
| Revenue | ★ $2,529,978,000.00 | $747,138,000.00 |
| Revenue This Year | $6.60 | $19.58 |
| Revenue Next Year | $6.15 | $15.95 |
| P/E Ratio | $21.92 | ★ N/A |
| Revenue Growth | 4.06 | ★ 26.24 |
| 52 Week Low | $385.00 | $92.52 |
| 52 Week High | $623.61 | $210.01 |
| Indicator | CHE | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 34.96 | 31.73 |
| Support Level | $385.00 | N/A |
| Resistance Level | $462.68 | $161.36 |
| Average True Range (ATR) | 12.45 | 5.55 |
| MACD | -2.45 | -0.63 |
| Stochastic Oscillator | 35.58 | 16.71 |
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. The company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.
iRhythm Holdings Inc formerly, iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.